Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection

NCT07149454 · clinicaltrials.gov ↗

PHASE1

Phase

ENROLLING_BY_INVITATION

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Tetanus

Interventions

DRUG: Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody Injection
DRUG: Human Tetanus Immunoglobulin
DRUG: Placebo

Sponsor

Lanzhou Institute of Biological Products Co., Ltd